Compare Sherwin-Williams Company (The) Common Stock (SHW) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sherwin-Williams Company (The) Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? Sherwin-Williams Company (The) Common Stock trades at $326.76 (market cap $78.68B), while Zimmer Biomet Holdings Inc trades at $92.24 (market cap $17.56B). The key difference: Sherwin-Williams Company (The) Common Stock is far larger — about 4.5× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.04%). Which is the better fit depends on your goals.
| SHW | ZBH | |
|---|---|---|
Market Cap | $78.68B | $17.56B |
Volume | 1,245,324 | 2,298,426 |
Sector | Basic Materials | Health |
52-Week High | $372.60 | $103.98 |
52-Week Low | $293.00 | $79.58 |
Enterprise Value | $92.60B | $24.63B |
Dividend Yield | 0.99% | 1.04% |
Typical Hold Time | — | 89 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sherwin-Williams (SHW) trades at $324.10, up 1.21% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals but maintains robust fundamentals with 65.12% ROE and expanding manufacturing capacity. Recent facility expansions in Statesville enhance production capabilities, positioning the company for continued market share gains.
Outlook remains positive with analyst consensus at Buy (57.9%) and $383.64 price target, though high valuation multiples (P/E 29.9) and competitive pressures present risks. Earnings growth and strategic investments support upside potential, while margin compression and economic sensitivity warrant monitoring.
Zimmer Biomet (ZBH) trades at $91.77, down 0.43% on the day, with a bullish technical signal supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady at $8.23B for 2025, though net income margins have moderated from 13.84% in 2023 to 8.56% in 2025. The company maintains strong profitability with a 69.87% gross margin and recently announced a $0.24 quarterly dividend.
ZBH presents a mixed outlook with positive earnings momentum and analyst consensus price target of $103.11 offering 12% upside potential. However, rising debt levels and competitive pressures in medical technology pose risks. Institutional ownership trends show continued interest, with State Street increasing its position by 0.6% in Q3 2026. The stock's valuation at 22.35 P/E appears reasonable given the company's market leadership position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sherwin-Williams Company (The) Common Stock
The Sherwin-Williams Company manufactures, develops, and distributes paints, coatings, and related products through three segments: Paint Stores Group, operating more than 4,900 company-owned stores selling Sherwin-Williams-branded products; Consumer Brands Group, selling brands such as Valspar, Dutch Boy, Krylon, and Minwax through mass merchandisers and home centers; and Performance Coatings Group, supplying industrial, construction, and transportation coatings in more than 120 countries.
Read more on SHW →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
